Eyenovia, Inc.
EYENDrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
Mydriasis
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)
Mydriasis
Pilocarpine Ophthalmic
Presbyopia
Phenylephrine 2.5% Eyedrop
Mydriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tropicamide/Phenylephrine ophthalmic solution (TR/PE) | Phase 3 | Mydriasis | - | - |
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE) | Phase 3 | Mydriasis | - | - |
Pilocarpine Ophthalmic | Phase 3 | Presbyopia | - | - |
Phenylephrine 2.5% Eyedrop | Phase 2 | Mydriasis | - | - |
Frequently asked questions
What is in Eyenovia, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Eyenovia, Inc.'s (EYEN) pipeline across Phase 3, Phase 2. Its lead program is Tropicamide/Phenylephrine ophthalmic solution (TR/PE) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eyenovia, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Eyenovia, Inc. (EYEN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EYEN biotech catalysts?→
Add EYEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eyenovia, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.